-transparent.png){kind=logo}
The phosphonylmethoxyalkyl derivatives HPMPA [(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine], HPMPC [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine] and PMEA [9-(2-phosphonylmethoxyethyl)adenine] were evaluated as 0.2% eyedrops for their efficacy in the treatment of experimental herpes simplex virus type 1 (HSV-1) keratitis in the rabbit model. BVDU 0.2% eyedrops were used as the reference treatment. HPMPA, HPMPC, PMEA and BVDU eyedrops showed a rapid and highly significant healing effect (P less than 0.005) on keratitis caused by TK+ HSV-1 (McIntyre strain) when compared with placebo eyedrops, whereas BVDU treatment did not affect the course of TK- HSV-1 (VMW-1837) keratitis. HPMPA and HPMPC treatment again caused a highly significant healing (P less than 0.005, compared with placebo eyedrops). Although PMEA eyedrops were less effective than HPMPA or HPMPC eyedrops, the effect of PMEA eyedrops was significantly (P less than 0.05) different from the effect of either BVDU or placebo eyedrops.
P C Maudgal, and
E De Clercq
February 2009,
Current eye research,
P C Maudgal, and
E De Clercq
December 1987,
Antiviral research,
P C Maudgal, and
E De Clercq
July 1991,
Antiviral research,
P C Maudgal, and
E De Clercq
February 1999,
Gene therapy,
P C Maudgal, and
E De Clercq
March 1987,
Yan ke xue bao = Eye science,
P C Maudgal, and
E De Clercq
January 1961,
Farmakologiia i toksikologiia,
P C Maudgal, and
E De Clercq
November 1990,
Journal of medical virology,
P C Maudgal, and
E De Clercq
January 1976,
Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
P C Maudgal, and
E De Clercq
January 1990,
Nucleic acids symposium series,
P C Maudgal, and
E De Clercq
January 1984,
Nucleic acids symposium series,
